Prevencio Receives FDA Breakthrough Device Designation for HART CADhs, Its Artificial Intelligence-driven Blood Test for Obstructive Coronary Artery Disease
HART CADhs is the only AI-based multi-protein blood test capable of accurately detecting blockage in the heart's arteries. By combining multiple cardiac proteins with proprietary machine learning algorithms, HART CADhs delivers actionable insight through a simple, non-invasive blood draw, bridging critical diagnostic gaps in current cardiovascular care.
"The FDA's Breakthrough Device Designation is a pivotal milestone in our mission to revolutionize the diagnosis and treatment of obstructive coronary artery disease," said Rhonda Rhyne, President and Chief Executive Officer of Prevencio. "We are committed to expanding the use of HART CADhs from outpatient settings into emergency care environments to ensure that patients receive earlier, more accurate, and potentially life-saving diagnoses."
HART CADhs is currently available as a Lab Developed Test (LDT) with a 2 to 10-day turnaround, making it ideal for evaluating stable, non-urgent patients. The Breakthrough Device Designation enables close collaboration with the FDA and an expedited review process, supporting Prevencio's goal to advance the test into a rapid, FDA-cleared in vitro diagnostic (IVD) with a one-hour result time—ideal for evaluating chest pain patients in emergency rooms.
HART CADhs was developed using Prevencio's proprietary HART platform in collaboration with researchers at Massachusetts General Hospital (MGH). In clinical research, the test demonstrated high accuracy (0.86 AUC) in detecting obstructive CAD, significantly outperforming standard-of-care tests such as stress echocardiography and nuclear imaging, which yielded only 0.52 AUC.
"With nearly half of U.S. counties lacking access to a cardiologist and long wait times in urban centers, a simple, accurate blood test to diagnose obstructive CAD offers tremendous potential to improve access to early diagnosis and intervention," said James L. Januzzi, MD, a practicing cardiologist at MGH, Professor of Medicine at Harvard Medical School, Chief Scientific Officer at the Baim Institute for Clinical Research and Principal Investigator for the HART test development and validation. "Our studies show HART CADhs is informative in a broad range of patient types including those with acute symptoms as well as those not diagnosed with a heart attack yet may have dangerous arterial obstruction. This suggests usefulness in both acute and outpatient settings."
Cardiovascular disease remains the leading cause of death in the United States and worldwide. According to the American Heart Association, cardiovascular disease and stroke account for over $318 billion in annual U.S. healthcare costs, nearly 10% of total healthcare spending. Prevencio's HART blood tests are designed to improve patient outcomes and reduce costs through earlier, more accurate, and more accessible diagnostics.
In addition to HART CADhs, Prevencio also offers HART CVE®, a second AI-driven, multi-protein blood test that assesses a patient's one-year risk of heart attack, stroke, or cardiovascular death. Both tests are currently available to healthcare providers.
About Prevencio HART Tests: Powered by AI, Prevencio is revolutionizing cardiac diagnostics with AI-driven blood tests for cardiovascular disease and custom diagnostics for diagnostic, medical device and pharmaceutical companies. Using this novel approach, the company has developed seven blood tests that significantly improve diagnosis and risk assessment for a variety of heart and blood vessel-related complications.
HART test results have been peer-reviewed published 35 times, including at leading cardiovascular meetings—(European Society of Cardiology Congress; American College of Cardiology Scientific Sessions; American Heart Association Scientific Sessions; American Diabetes Association Scientific Sessions; and Transcatheter Cardiovascular Therapeutics Sessions) and in top-tier journals—(Journal of American College of Cardiology; American Journal of Cardiology; Clinical Cardiology; Biomarkers in Medicine; Journal of American Heart Association; and European Journal of Preventive Cardiology).
About Prevencio, Inc.
Prevencio's vision is to revolutionize cardiac diagnostics with AI-driven blood tests—thereby improving care with highly accessible, accurate and cost-effective diagnosis and earlier treatment. Prevencio utilizes Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary Algorithms to deliver diagnostic & prognostic tests that are significantly more accurate than standard-of-care stress tests, genetic risk scores and coronary artery calcium. The company is headquartered in Kirkland, Washington. For additional information, visit Prevencio, Inc.
Forward-Looking (Safe Harbor) Statement:
Except for historical and factual information contained herein, this press release contains forward-looking statements, such as market need, acceptance, and size, the accuracy of which is necessarily subject to various uncertainties of development-stage companies. The company does not undertake to update disclosures contained in this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250513396732/en/
Contacts
Christiaan Boer, cboer@cplusc.com; 206-557-4309
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
2 hours ago
- Time Business News
Brighten Your Skin Safely: Why Hydroquinone 4% Cream Remains the Gold Standard for Hyperpigmentation
In the world of skincare, achieving a flawless, even-toned complexion is often a top goal. Whether you're dealing with dark spots, melasma, age spots, or acne scars, hydroquinone cream 4 percent remains one of the most trusted and dermatologist-recommended treatments for fading hyperpigmentation. If you're looking to understand how it works, what results to expect, and where to buy hydroquinone 4% cream online, this in-depth guide is for you. What is Hydroquinone 4% Cream? Hydroquinone is a skin-lightening agent that works by inhibiting tyrosinase, an enzyme responsible for the production of melanin (the pigment that gives skin its color). At a concentration of 4%, it's considered the most effective over-the-counter strength for treating moderate to severe hyperpigmentation. Common skin concerns treated with hydroquinone 4% cream include: Melasma Age spots Post-inflammatory hyperpigmentation (PIH) Acne scarring Freckles and sunspots This strength is typically recommended for individuals who have previously used lighter concentrations (like 2%) and are looking for more dramatic, faster results. Benefits of Hydroquinone 4% Cream The advantages of using hydroquinone cream at 4% strength are clear and well-documented: Rapid Fading of Dark Spots: Noticeable improvement in 4–6 weeks of consistent use. Noticeable improvement in 4–6 weeks of consistent use. Evens Out Skin Tone: Helps reduce blotchiness and patchiness. Helps reduce blotchiness and patchiness. Minimal Downtime: Non-invasive and easy to apply at home. Non-invasive and easy to apply at home. Dermatologist Recommended: A top choice in skin clinics for decades. People often search for terms like 'hydroquinone 4 cream results' or 'hydroquinone 4 cream before and after pictures' to see real-life transformations. A consistent regimen, combined with sun protection, makes all the difference. How to Use Hydroquinone 4% Cream Correctly To ensure maximum benefits while avoiding irritation or side effects, follow these steps: Cleanse: Wash your face with a mild, non-irritating cleanser. Apply Thin Layer: Use a small amount of hydroquinone cream on the affected area only. Moisturize: Wait a few minutes and apply a hydrating, non-comedogenic moisturizer. Sunscreen is Non-Negotiable: Always use broad-spectrum SPF 30 or higher during the day. Use Once Daily: Usually applied at night, unless otherwise instructed by a healthcare provider. Avoid using with products that contain benzoyl peroxide, AHAs, or vitamin C initially, as they may cause irritation. Hydroquinone Cream 4% vs. Other Bleaching Creams Some people wonder whether 'hydroquinone bleaching cream' is safe or if they should opt for natural alternatives. While hydroquinone is technically a bleaching agent, it is FDA-approved and widely used in clinical dermatology. Compared to natural alternatives, hydroquinone: Works faster and more effectively Is supported by decades of clinical studies Targets pigment directly at the source (melanin production) It's important to follow usage instructions and take breaks (often 3 months on, 1 month off) to prevent overuse. Understanding Hydroquinone 4 Cream Price and Accessibility The hydroquinone 4 cream price can vary significantly depending on the brand and where you purchase it. In the U.S., prescription formulations may cost $60–$100 or more. Fortunately, you can buy hydroquinone online from trusted international pharmacies like OKDERMO at a much more affordable rate—without a prescription in many regions. This makes it easier to access professional-grade skincare without paying a premium or visiting a dermatologist. Where to Buy Hydroquinone 4 Cream Online Safely While some turn to large marketplaces and search 'hydroquinone 4 cream Amazon,' it's important to be cautious. Not all listings guarantee authenticity or proper storage. Buying from a specialty skincare provider like OKDERMO ensures: Pharmaceutical-grade product Proper packaging and shipping Trusted customer service and global delivery OKDERMO carries Melalite 4 Cream, a well-known brand that delivers powerful skin-lightening results using 4% hydroquinone. Before and After Expectations Seeing hydroquinone 4 cream before and after pictures can be highly motivating. Most users report visible changes within 4 to 6 weeks, with optimal results seen after 2 to 3 months of regular use. Note: Hydroquinone results are not immediate. It requires consistent application, sun protection, and patience. Once the desired skin tone is achieved, dermatologists typically recommend discontinuing use or switching to maintenance products to avoid over-depigmentation. Safety and Precautions While hydroquinone is safe for most users, it's important to use it correctly and monitor your skin's reaction: Do not use on broken or inflamed skin. Avoid long-term use without breaks. A 3-month cycle is often recommended. A 3-month cycle is often recommended. Consult a dermatologist if you experience severe redness, burning, or unusual pigmentation changes. Always do a patch test before applying it to larger areas. Final Thoughts If you're seeking a reliable and effective solution to dark spots and uneven skin tone, hydroquinone 4% cream stands out as the gold standard. Backed by decades of medical use and clinical evidence, it delivers visible results in a matter of weeks. Rather than risking unknown sellers or overpriced prescriptions, buy directly from a trusted source. OKDERMO's Melalite 4 Cream offers pharmaceutical-grade strength and proven outcomes at an affordable price—no prescription required. TIME BUSINESS NEWS
Bloomberg
2 hours ago
- Bloomberg
When an HIV Scientific Breakthrough Isn't Enough
A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food and Drug Administration last month. Gilead Sciences' lenacapavir is so effective that global health leaders had started to cautiously talk about the end of an epidemic that continues to kill more than 600,000 people each year. We should be celebrating its arrival.
Yahoo
14 hours ago
- Yahoo
ACHV: Achieve's Busy Day
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted a flurry of press releases last week announcing the submission of its new drug application (NDA), a partnership with Omnicom for cytisinicline commercialization, a proposed public offering and the pricing of the offering. The capital raise was closed on June 30th. This is the culmination of more than a decade of work developing cytisinicline for smoking cessation. Now that the development phase of cytisinicline for smoking cessation is coming to a close, we look towards the regulatory and commercialization phases. We expect to see the FDA formally accept the NDA by late August and Achieve's management team to turn its attention towards the sales effort. Assuming normal turnaround times, we expect the FDA to set a target action date sometime in 2Q:26. NDA Submission Achieve announced its NDA submission of cytisinicline for smoking cessation in a June 26th press release. The company conducted two Phase III studies, an open label safety study and other studies that evaluated over 2,000 participants with the results demonstrating the safety, efficacy and tolerability of cytisinicline. We expect to see acceptance of the NDA within 60 days and further expect additional safety data from the ongoing ORCA-OL trial to be shared with the agency near year end. Commercialization Partnership Now that the new drug application has been submitted, Achieve is further advancing its commercialization efforts. During its earnings calls, the company has outlined its commercialization strategy and is now partnering with Omnicom Group to execute the plan. Omnicom Group provides brand and advertising services to thousands of clients globally and is one of the world's largest advertising and marketing services companies. Achieve will work with Omnicom subsidiary Credera, which is focused on digital transformation services. Credera combines consulting, artificial intelligence (AI) and technology expertise to build consumer technology platforms, integrate marketing technology systems and provide strategic consulting services. It will help Achieve to precisely target and engage healthcare professionals and patients through optimization of channel performance and acceleration of meaningful engagement. The team executing the initiative will include Goodby, Silverstein & Partners, DDB Health, and Ketchum Health which are health care-focused subsidiaries of the Omnicom marketing group. The various subsidiaries will provide expertise in consumer brand development, medical education and strategic public relations and communications, applying industry insights to support cytisinicline launch. In the Achieve partnership, Ketchum Health brings public relations and communications expertise, while Credera handles technology, Goodby Silverstein provides creative advertising, and DDB Health focuses on healthcare marketing. The partnership will use generative AI, predictive analytics and social listening to enhance targeting and personalization. Using a comprehensive approach, it will also employ healthcare applications, pharmacies and data providers to expand the reach and depth of insights. Omnicom has worked as media agency, digital and brand experience for other pharmaceutical and biotechnology clients including established firms such as AbbVie, AstraZeneca, Novartis and Moderna among others. Achieve will be the first small company that Omnicom has supported in commercializing a newly approved drug. Therefore, Omnicom will take on a broader strategic role than in its past partnerships. The Omnicom team will help communicate the optimal message to the provider and patient and monitor its effectiveness in real time. This will allow for rapid course corrections and focus on high value activities. Achieve has identified several target groups for its marketing efforts that are stratified by age, social media use and other demographic data. It was able to identify these groups based on subject experiences in the company's many clinical trials. We anticipate that the structure of Achieve's internal marketing team will be heavily tilted toward supporting the digital campaign with contract representatives available for in-person physician meetings when appropriate. Public Offering On June 30th, 2025 Achieve closed its $45 million capital raise. 15 million shares were issued at $3.00, each of which included an attached warrant exercisable at $3.00 per share. An additional 1,766,666 warrants were issued upon the partial exercise by the underwriters of their option to purchase additional shares, bringing total issued warrants to approximately 16.8 million. Net proceeds from the capital raise are estimated to be $41.3 million as disclosed in the June 27th Form 8-K filing. ORCA-OL Safety Trial Achieve began 2025 by announcing that 300 participants had completed six months of treatment in the Ongoing Research of Cytisinicline for Addiction Program, Open Label (ORCA-OL) trial. The Data Safety Monitoring Committee (DSMC) identified no safety concerns as of this milestone allowing registrational filing with the FDA. As of May 2025, a third DSMC safety review was completed which also found no unexpected treatment-related adverse events. As of the first quarter reporting date, more than 100 subjects had completed one year of cytisinicline treatment. Furthermore, about 75% of the 479 (~360) individuals remained on treatment in the trial. We think that it is a material real-world positive that so many participants would remain on a smoking cessation product for that long a period suggesting that cytisinicline is well tolerated. This is particularly notable given the high discontinuation rates for Chantix and the associated unpleasant side effects such as nausea, headache, abnormal dreams and constipation.[1] Achieve expects to complete the one-year safety data package in the next few months and will submit this to the FDA by the 120-day safety review milestone. This should be around year-end 2025. Achieve expects that it will far exceed the 100-patient minimum required for one year of safety observations and could see as many as 300 patients with one year of exposure. Since one of the secondary endpoints is efficacy, this study should be able to show a wealth of data that can help providers use cytisinicline more effectively especially in chronic areas of disease such as Chronic Obstructive Pulmonary Disease (COPD) and cardiology. Milestones Development of cytisinicline product label for smoking cessation – 1H:25 Completion of six months of ORCA-OL safety data for 300 subjects – January 2025 Attendance at Oppenheimer Healthcare Life Sciences Conference, Virtual – February 2025 Attendance at Barclays Healthcare Conference, Miami – March 2025 Selection of 3rd party logistics partner – 2Q:25 NDA Submission – 2Q:25 FDA data submission from patients with twelve months of exposure to cytisinicline – 4Q:25 Launch of Phase III vaping trial – 1H:26 FDA target action date for cytisinicline NDA – 1H:26 Launch of cytisinicline – 3Q:26 SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer . ________________________ [1] Minian, N., et al. Identifying determinants of varenicline adherence using the Theoretical Domains framework: a rapid review. BMC Public Health. March 2024.
